Foundation Medicine Identifies Patients Likely to Respond to Certain MET Inhibitor Targeted Therapies; Durable Responses in Non-Small Cell Lung Cancer (NSCLC) Presented at ASCO Annual Meeting
Data Support Role of MET Exon 14 Alterations as a Viable Therapeutic Target and Highlight Need for Reimbursement of Comprehensive Genomic Profiling in Leading Cancer Killer
Identification of this patient population by comprehensive genomic profiling with FoundationOne® is an important step towards making targeted therapy available for a wider range of patients with NSCLC. Further, the addition of METex14 alterations to the growing list of oncogenic drivers in NSCLC supports the need for broad reimbursement coverage of comprehensive genomic profiling to allow a full understanding of the genomic drivers of a patient's tumor and the matched targeted therapeutic approaches to drive improved outcomes.
"Due to the diversity of METex14 alterations, many of these alterations
can only be detected in the clinical setting using comprehensive genomic
profiling methods, such as FoundationOne," said
"There is an ever-increasing body of clinical evidence demonstrating
that comprehensive genomic profiling is an important and necessary step
to stratify patients for appropriate targeted therapy, and by conducting
such profiling, to optimize the opportunity for improved outcomes," said
Focal amplification and certain activating, albeit uncommon, point
mutations of MET are well-characterized oncogenic drivers that
confer susceptibility to targeted MET inhibitors. However, the full
diversity and prevalence of recurrent somatic splice site alterations at
METex14 that result in exon skipping and MET activation were previously
unknown. Researchers from
These data were presented today in an oral presentation at the 2015
These data expand on previously published data in Cancer Discovery1.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of FoundationOne to identify specific clinically relevant genomic alterations and targeted therapies for a wider range of patients, the utility of FoundationOne in informing treatment of certain patient populations, the need for broad reimbursement coverage of comprehensive genomic profiling, and clinical data related to FoundationOne and certain genomic alterations. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that Foundation Medicine's products will not be able to identify genomic alterations in the same manner as prior data; and the risks described under the caption "Risk Factors" in Foundation Medicine's Annual Report on Form 10-K for the year ended December 31, 2014, which is on file with the Securities and Exchange Commission, as well as other risks detailed in Foundation Medicine's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.
1. Frampton, G. et al. Activation of MET via diverse exon 14 splicing
alterations occurs in multiple tumor types and confers clinical
sensitivity to MET inhibitors. Cancer Discovery CD-15-0285; Published
News Provided by Acquire Media